Caliway Biopharmaceuticals Co. L
6919
Peringkat dalam Saham
#4343
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Harga Saham
$2.29
Kapitalisasi Pasar
$3.56B
Perubahan (1 hari)
-2.50%
Perubahan (1 tahun)
-57.22%
Negara
TW
Perdagangan Caliway Biopharmaceuticals Co. L (6919)
Kategori
Healthcare
Riwayat hasil dividen untuk Caliway Biopharmaceuticals Co. L (6919)
Hasil dividen (TTM) dari Caliway Biopharmaceuticals Co. L (simbol saham: 6919) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Caliway Biopharmaceuticals Co. L (6919) dari 2025 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| 2025 | 0.00% | 0.00% |
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
